Xvivo Perfusion AB (XVIVO) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Xvivo Perfusion AB stock SEK 80.22, price SEK 205, upside -60.8%, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?No
Quality 50+?No
In an uptrend?Yes
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range kr 129.80 – kr 539.00 · fair‑value band kr 57.18 – kr 103.26 · the kr 204.80 price screens above the kr 80.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Oct 27, 2026.
Follow Xvivo Perfusion in your weekly email
Every Wednesday you see whether Xvivo Perfusion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments.
Show moreShow less
The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient.
It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment.
In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation.
It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
Stock analysis
Xvivo Perfusion AB (XVIVO) currently trades at kr 204.80, while our model-based Fair Value estimate is kr 80.22, 60.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 81.72 per share, and 0 of the 23 models we run sit above the kr 204.80 price.
Bear case: the Asset-Based group reads lowest at kr 13.57, and 23 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: kr 57.18 (bear) to kr 103.26 (bull), the price of kr 204.80 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Xvivo Perfusion AB reported revenue of 812M SEK in FY2025 versus 258M SEK in FY2021, a compound +33.2%/yr. Reported net income was 25.2M SEK in FY2025, compounding +32.5%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 6.5B SEK (≈ $652M) Small · P/E ratio 72.6 · P/S ratio 2.25 · EPS (TTM) kr 2.82 · Net margin 3.1% · Return on equity 5.9% · Return on assets (EBIT) 1.9% · Operating margin 11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 44 out of 100 (low confidence).
What moves the price
The share trades about 34% below its 52-week high and 26% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −61%, XVIVO screens richer than that median.
Fair Value models
Bearkr 57.18Fair Value kr 80.22Bullkr 103.26
Price kr 204.80 · Upside -60.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 2.33 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.2%
Start year 2020 (pandemic). Over 10 years: +21.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+27.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+27.9%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.27.9% vs 16.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−19% → 12%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+38.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+20.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +36.0% a year for the price and +17.7% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 322 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−60.8% · Below median
Profitability
Return on equity (12 months)5.9% · Above median
Return on assets1.1% · Below median
Net margin (12 months)13.4% · Above median
Operating margin (12 months)11.1% · Above median
Growth and dividend
Revenue growth (quarter YoY)33.5% · Top 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)72.6× · Priciest 25%
P/B3.05× · Pricier than median
P/S (12 months)6.73× · Priciest 25%
Price / free cash flow63.9× · Priciest 25%
EV/EBITDA34.9× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 8
FUTURE (revenue growth)100· sector 34
PAST (return on equity)24· sector 17
HEALTH (low debt)98· sector 98
DIVIDEND (yield)0· sector 35
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Xvivo Perfusion AB Fair Value". https://www.fairvalue-calculator.com/stock/XVIVO
Frequently asked questions
Is Xvivo Perfusion AB (XVIVO) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of kr 80.22 versus a price of kr 204.80, about −61% upside (overvalued).
What is the fair value of XVIVO?
Our model-based fair value for Xvivo Perfusion AB is kr 80.22 (as of Oct 27, 2026), built from audited fundamentals. The current price: kr 204.80.
What is the quality score of XVIVO?
Xvivo Perfusion AB has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Xvivo Perfusion AB (XVIVO)?
Our model-based price target is the fair value of kr 80.22 (as of Oct 27, 2026) from 23 valuation models. Cautious scenario kr 57.18, optimistic scenario kr 103.26. It is a calculation from audited fundamentals, not an analyst target.
What is the Xvivo Perfusion AB stock forecast for 2026?
Our models put fair value at kr 80.22, about −61% upside versus a price of kr 204.80 (overvalued). Cautious scenario kr 57.18, optimistic scenario kr 103.26. The calculation is refreshed regularly with new filings.
What is the revenue of Xvivo Perfusion AB (XVIVO)?
Xvivo Perfusion AB reported trailing-twelve-month revenue of about 959M SEK (latest available figure, as of Oct 27, 2026).
What growth is priced into Xvivo Perfusion AB (XVIVO)?
For today's price to be fair in a discounted-cash-flow model, Xvivo Perfusion AB would have to grow free cash flow by +38.7 % per year for five years (discount rate 12.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +35.2 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of XVIVO use?
Our models discount Xvivo Perfusion AB at 12.3 %: a base by market capitalisation (small), damped by beta 1.47, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Xvivo Perfusion AB that is +38.7 % per year a year over ten years, using the same discount rate (12.3 %) and the same formula as our fair value.
How much growth has Xvivo Perfusion AB (XVIVO) delivered so far?
Over the past 5 years revenue at Xvivo Perfusion AB grew +35.2 % a year. The price currently implies +38.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Xvivo Perfusion AB (XVIVO) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into Xvivo Perfusion AB (+38.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Xvivo Perfusion AB (XVIVO)?
The free-cash-flow yield on the price is 1.57 %: that much free cash flow Xvivo Perfusion AB produces per unit of market value. When it exceeds the discount rate of our models (12.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Xvivo Perfusion AB (XVIVO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Xvivo Perfusion AB it is kr 80.22 per share (as of Oct 27, 2026), against a price of kr 204.80. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Xvivo Perfusion AB stock overvalued or undervalued in 2026?
As of Oct 27, 2026, XVIVO trades above its calculated fair value: price kr 204.80, fair value kr 80.22, a gap of about −61% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XVIVO?
No. The price is what the market pays today (kr 204.80); the fair value is what the company's own numbers justify (kr 80.22). For Xvivo Perfusion AB the two are kr 124.58 per share apart. That gap is exactly why we show both numbers side by side.
How much is Xvivo Perfusion AB worth?
The market values Xvivo Perfusion AB at about 6.5B SEK (market capitalisation, as of Oct 27, 2026). Per share that is kr 204.80; our models calculate a fair value of kr 80.22 per share.
What do the bullish and bearish scenarios say about XVIVO?
Our models span a range for Xvivo Perfusion AB: cautious scenario kr 57.18, base kr 80.22, optimistic kr 103.26 per share (as of Oct 27, 2026, price kr 204.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of XVIVO?
Xvivo Perfusion AB trades at a price-to-earnings ratio of 72.6 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 80.22 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 240.6 (reported for FY2025: 256.8). Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2025 ex one-offs: 293.2. Other multiples: P/B 3.1, P/S 6.7, EV/EBITDA 34.9.
How solid is the balance sheet of Xvivo Perfusion AB (XVIVO)?
Balance-sheet figures for Xvivo Perfusion AB (as of Oct 27, 2026): return on equity 5.9%, debt of 0.04 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is XVIVO from its 52-week high?
Xvivo Perfusion AB trades at kr 204.80, about 34% below its 52-week high of kr 309.00 and 26% above the low of kr 162.40 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of kr 80.22 is for.
Which stocks are comparable to Xvivo Perfusion AB?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Xvivo Perfusion AB stock attractive at the current price?
The data as of Oct 27, 2026: price kr 204.80, calculated fair value kr 80.22 (−61%), Quality Score 47/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XVIVO calculated?
We run Xvivo Perfusion AB through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 80.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Xvivo Perfusion AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Xvivo Perfusion AB (XVIVO)?
The closing price on Oct 28, 2026 was kr 204.80. Our model-based fair value is kr 80.22, about −61% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Xvivo Perfusion AB right now?
The price sits above even our optimistic bull case (kr 103.26). The favourable scenario is already priced in. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (kr 57.18 to kr 103.26) leaves room in how you read the outcome.
Where does the earnings growth of Xvivo Perfusion AB (XVIVO) come from?
Earnings per share at Xvivo Perfusion AB grew +39.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +18.3 %, EBIT margin +6.2 %, tax rate +4.1 %, residual (interest, one-offs) +6.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Xvivo Perfusion AB
How large is the market capitalisation of Xvivo Perfusion AB (XVIVO)?
The market capitalisation of Xvivo Perfusion AB is 6.5B SEK (≈ $652M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Xvivo Perfusion AB (XVIVO)?
The price-to-sales ratio of Xvivo Perfusion AB is 2.25 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Xvivo Perfusion AB (XVIVO)?
Earnings per share at Xvivo Perfusion AB are kr 2.82 (price ÷ EPS = P/E 72.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Xvivo Perfusion AB (XVIVO)?
The net margin of Xvivo Perfusion AB is 3.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Xvivo Perfusion AB (XVIVO)?
The return on equity (ROE) of Xvivo Perfusion AB is 5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Xvivo Perfusion AB (XVIVO)?
On an EBIT basis the return on assets of Xvivo Perfusion AB is 1.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Xvivo Perfusion AB (XVIVO)?
The operating margin of Xvivo Perfusion AB is 11.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Xvivo Perfusion AB (XVIVO)?
Revenue at Xvivo Perfusion AB is growing +33.5% versus a year earlier (3y avg +25.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Xvivo Perfusion AB (XVIVO)?
Earnings per share at Xvivo Perfusion AB are growing +928% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Xvivo Perfusion AB (XVIVO) hold?
Xvivo Perfusion AB holds more cash than debt, 54.2M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Xvivo Perfusion AB in the live analysis
One click puts Xvivo Perfusion AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 27, 2026